Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on C Glycosylation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN111233949A details a novel one-pot three-enzyme method for GM3 synthesis, offering high stereoselectivity and cost reduction for pharmaceutical intermediate manufacturing.
Patent CN119654332A reveals a stereoselective route for DNMT1 inhibitor intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN112159447B details a novel DMAP-catalyzed route for 2-chloroadenosine, offering superior purity and yield while eliminating heavy metal contamination for scalable API production.
Patent CN112480197B reveals a cost-effective route for cytosine nucleoside using cyanoacetaldehyde urea acetal, offering significant supply chain advantages.
Patent CN101497639B details a scalable Decitabine synthesis using toluoyl protection and fractional crystallization, offering significant cost reduction in pharmaceutical manufacturing.
Patent CN103665064B details a novel three-step synthesis for high-purity sugar intermediates, offering significant cost reduction and scalable manufacturing solutions.
Patent CN113461743A reveals a cost-effective 4-step route for crosslinkable nucleosides, eliminating chromatography and enabling high-purity oligonucleotide manufacturing.
Patent CN116217633B details chemical synthesis avoiding enzymes. Enables scalable production and cost reduction for nutritional ingredient supply chains.
Novel catalytic route for Capecitabine using 5-deoxy-D-ribofuranose derivatives, offering high yield and mild conditions for API manufacturing.
Patent CN108239128A reveals TMSOTf catalysis for high-purity beta-nucleosides. Enhances supply chain reliability and cost reduction in pharma manufacturing.
Patent CN107573311A reveals a cost-effective Dapagliflozin route using 4-methylphenol. This method ensures high purity and scalable manufacturing for global supply chains.
Patent CN109912642A enables high-purity pharmaceutical intermediates via novel protecting group strategy ensuring supply chain reliability and cost efficiency for global buyers.
Novel 3-step synthesis of Cytosine Nucleoside from cyanoacetaldehyde urea acetal. High yield, cost-effective route for antiviral API manufacturing.
Patent CN111377982B details a novel solid acid catalyzed glycosylation for decitabine intermediates, offering high beta-selectivity and simplified purification for pharmaceutical manufacturing.
Patent CN108440623A reveals a novel silylation-free route for Capecitabine Intermediate. Achieve higher purity and reduced manufacturing costs with scalable supply.
Patent CN108610386A reveals a scalable synthesis for hexuronic acid glycosides. Achieve high purity and cost reduction in pharmaceutical intermediate manufacturing with our advanced catalytic process.
Patent CN108373491B reveals a cost-effective chemical route for nelarabine using cyclocytidine and TMSOTf catalysis, offering significant supply chain advantages.
Patent CN115073540A reveals a modular chemical synthesis for high-purity inulin-type fructooligosaccharides, offering superior supply chain reliability and cost efficiency.
Patent CN113861246B introduces a novel stereoselective synthesis method enhancing purity and yield for pharmaceutical intermediates, offering significant supply chain and cost advantages.
Novel cobalt-catalyzed method for diabetes drug intermediates. Reduces cost and improves supply chain reliability significantly for global buyers seeking scalable solutions.